Journal Information
Vol. 46. Issue 8.
Pages 442-444 (January 2010)
Share
Share
Download PDF
More article options
Vol. 46. Issue 8.
Pages 442-444 (January 2010)
Case Report
Full text access
Organizing Pneumonia Associated with the Use of Trastuzumab
Neumonía organizada asociada a tratamiento con trastuzumab
Visits
5271
Álvaro Taus-Garcíaa, Albert Sánchez-Fontb,
Corresponding author
asanchezf@imas.imim.es

Corresponding author.
, Sònia Servitja-Tormoa, Lara Pijuanc, José María Maiques-Llácerd, Víctor Curullb
a Servei d’Oncologia Mèdica, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Universitat Pompeu Fabra, Barcelona, Spain
b Servei de Pneumologia, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Universitat Pompeu Fabra, CIBER de Enfermedades Respiratorias (CibeRes), Barcelona, Spain
c Servei d’Anatomia Patològica, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Universitat Pompeu Fabra, Barcelona, Spain
d Servei de Radiodiagnòstic, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Universitat Pompeu Fabra, Barcelona, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract

Organizing pneumonia is a clinical and histological condition in which the onset is usually subacute with respiratory symptoms and pulmonary infiltrates. It may be unknown origin (cryptogenic) or associated with other illnesses, infectious diseases or drugs. We present a 60 year-old female patient with a previous history of breast cancer, who was being treated with trastuzumab, an antiHER2 monoclonal antibody. She was diagnosed with casual pulmonary infiltrates that had histological changes compatible with organizing pneumonia. The pulmonary infiltrates disappeared on withdrawing trastuzumab treatment. Due to the increasing use of biological therapies in different medical areas, we believe it is of interest to report this pulmonary involvement attributed to the monoclonal antibody trastuzumab.

Keywords:
Organizing pneumonia
Trastuzumab
Herceptin®
Breast cancer
Resumen

La neumonía organizada es una entidad clinicohistológica que suele manifestarse de forma subaguda con clínica respiratoria e infiltrados pulmonares. Puede ser de causa desconocida (criptogenética) o estar asociada a distintas enfermedades, infecciones o fármacos. Presentamos el caso de una paciente de 60 años con antecedentes de una neoplasia de mama, motivo por el cual seguía tratamiento con trastuzumab, un anticuerpo monoclonal anti-HER2, a quien se detectó de forma casual un infiltrado pulmonar, cuya biopsia transbronquial fue diagnóstica de neumonía organizada. Tras la retirada del fármaco desapareció el infiltrado pulmonar. Debido a la creciente utilización de la terapia biológica en diferentes campos de la clínica, nos parece de interés comunicar esta forma de afectación pulmonar atribuible al anticuerpo monoclonal trastuzumab.

Palabras clave:
Neumonía organizada
Trastuzumab
Herceptin®
Cáncer de mama
Full text is only aviable in PDF
References
[1.]
A. Xaubet, J. Ancochea, R. Blanquer, C. Montero, F. Morell, E. Rodríguez Becerra, et al.
Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas.
Arch Bronconeumol, 39 (2003), pp. 580-600
[2.]
American Thoracic Society; European Respiratory Society.
American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.
Am J Respir Crit Care Med, 165 (2002), pp. 277-304
[3.]
P.H. Camus, P. Foucher, P.H. Bonniaud, K. Ask.
Drug-induced infiltrative lung disease.
Eur Respir J Suppl, 32 (2001), pp. 93S-100S
[4.]
The Drugs-Induced Lung Diseases Available from: http://www.pneumotox.com.
[5.]
Y. Yarden, M.X. Sliwkowski.
Untangling the ErbB signalling network.
Nat Rev Mol Cell Biol, 2 (2001), pp. 127-137
[6.]
A. Gschwind, O.M. Fischer, A. Ullrich.
The discovery of receptor tyrosine kinases: targets for cancer therapy.
Nat Rev Cancer, 4 (2004), pp. 361-370
[7.]
D.J. Slamon, G.M. Clark, S.G. Wong.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science, 235 (1987), pp. 177-182
[8.]
B. Vahid, A. Mehrotra.
Trastuzumab (Herceptin)-associated lung injury.
Respirology, 11 (2006), pp. 655-658
[9.]
E. Radzikowska, E. Szczepulska, M. Chabowski, I. Bestry.
Organising pneumonia caused by trastuzumab (Herceptin) therapy for breast cancer.
Eur Respir J, 21 (2003), pp. 552-555
[10.]
N.S. Irey.
Teaching monograph. Tissue reactions to drugs.
Am J Pathol, 82 (2006), pp. 613-647
[11.]
M. Soubrier, G. Jeannin, J.L. Kemeny, A. Tournadre, N. Caillot, D. Caillaud, et al.
Organizing pneumonia after rituximab therapy: two cases.
Joint Bone Spine, 75 (2008), pp. 362-365
[12.]
Lioté H, Lioté F, Séroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: a systematic literature review. Eur Respir J. In press 2009.
[13.]
K. Akita, A. Ikawa, S. Shimizu, K. Tsuboi, K. Ishihara, S. Sato, et al.
Cryptogenic organizing pneumonia after radiotherapy for breast cancer.
Breast Cancer, 12 (2005), pp. 243-247
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?